Skip to Main Content

The Food and Drug Administration is convening a meeting of outside experts today to review clinical data on an experimental treatment for ALS from Amylyx Pharmaceuticals. The stakes for this all-day meeting are high, and deliberations could be contentious.

Patients with ALS, their caregivers, and advocacy groups have been applying enormous pressure on the FDA to approve the Amylyx drug, called AMX0035, which they see as a vitally necessary treatment against a neurodegenerative disease that is almost universally fatal.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment